L523S: A Potential Target for Lung Cancer Treatment
Author Information
Author(s): Wang T, Fan L, Watanabe Y, McNeill P D, Moulton G G, Bangur C, Fanger G R, Okada M, Inoue Y, Persing D H, Reed S G
Primary Institution: Corixa Corporation
Hypothesis
Can L523S, an RNA-binding protein, serve as a therapeutic target for lung cancer?
Conclusion
L523S is overexpressed in lung cancer and may be a valuable target for immunotherapy.
Supporting Evidence
- L523S was overexpressed in 21 of 26 squamous cell carcinoma samples.
- 90% of lung squamous cell carcinoma and adenocarcinoma samples showed positive L523S immunoreactivity.
- Antibody responses to L523S were detected in 8 out of 17 lung cancer patients.
Takeaway
Researchers found a protein called L523S that is found a lot in lung cancer, which could help create new treatments.
Methodology
The study used high throughput methods, cDNA microarray analysis, and real-time PCR to evaluate L523S expression in lung cancer samples.
Limitations
The study did not address the possibility of immune complexes affecting antibody detection.
Participant Demographics
The study included lung cancer patients with various stages of the disease.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website